[SCHEDULE 13G] TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filing

Rhea-AI Filing Summary

Harel Insurance Investments & Financial Services Ltd. reported ownership of 58,118,222 ordinary shares of Teva Pharmaceutical Industries Ltd, representing 5.1% of the class based on 1,147,150,917 shares outstanding as of June 30, 2025. Most shares are held on behalf of public clients: 56,881,124 for pooled public funds, 114,084 in third-party client accounts (with no voting power), and 1,123,014 beneficially held for Harel's own account. The filing shows shared voting power of 58,004,138 and shared dispositive power of 58,118,222. The statement clarifies these holdings are not intended to affect control of the issuer and discloses Israeli organization and office addresses.

Positive

• Crossed 5% threshold, prompting transparent disclosure of a meaningful institutional stake (58,118,222 shares, 5.1%)
• Majority held for public clients (56,881,124 shares), indicating diversified, fiduciary positioning rather than concentrated proprietary risk
• Filing clarifies voting structure with 0 sole voting power and 58,004,138 shared voting power, reducing signals of unilateral control

Negative

• Material position but limited proprietary skin: only 1,123,014 shares held for Harel's own account (small relative to total position)
• Shared voting power and independent sub-manager decisions mean the filing offers limited insight into future voting outcomes or coordinated actions

Insights

Equity Ownership Analyst

Harel holds a passive, >5% stake in TEVA largely for client accounts.

Harel reports 58.1M shares or 5.1% of Teva, crossing the 5% disclosure threshold that notifies investors of meaningful institutional ownership. The bulk of the position (56.9M) is held for public pooled vehicles managed by subsidiaries that exercise independent voting.

This structure implies Harel is a material institutional holder but attributes active voting to independent sub-managers, reducing the filing's signal of coordinated control or strategic activism.

Corporate Governance Specialist

Voting and dispositive power are largely shared, not sole.

The filing lists 0 shares of sole voting power and 58.0M of shared voting power, indicating that Harel does not claim unilateral control. It also discloses only 1.12M shares beneficially held for Harel's own account, which is small relative to its total reported position.

Because the statement affirms the shares are not held to influence control, this looks like a regulatory disclosure of sizeable passive/institutional exposure rather than an active governance intent.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Teva Pharmaceutical Industries Ltd

(Name of Issuer)

Ordinary Shares, par value NIS 0.10 per share

(Title of Class of Securities)

M8769Q102

(CUSIP Number)

09/29/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. M8769Q102

1

Names of Reporting Persons

Harel Insurance Investments & Financial Services Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

ISRAEL

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 58,004,138.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 58,118,222.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

58,118,222.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: * With regard to the date of event that requires filing, see the explanatory note in Item 4. With regard to Rows (6), (8) and (9), please see Item 4. Row (11) is based on 1,147,150,917 Ordinary Shares issued and outstanding as of June 30, 2025 (as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 30, 2025).

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Teva Pharmaceutical Industries Ltd
(b)	Address of issuer's principal executive offices: 124 Dvora Hanevi'a Street, Tel Aviv, Israel, 6944020
Item 2.
(a)	Name of person filing: Harel Insurance Investments & Financial Services Ltd.
(b)	Address or principal business office or, if none, residence: 3 Aba Hillel Street, Ramat Gan 52118, Israel
(c)	Citizenship: Israel
(d)	Title of class of securities: Ordinary Shares, par value NIS 0.10 per share
(e)	CUSIP No.: M8769Q102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Of the 58,118,222 Ordinary Shares reported in this Statement as beneficially owned by the Reporting Person, (i) 56,881,124 Ordinary Shares are held for members of the public through, among others, provident funds and/or mutual funds and/or pension funds and/or insurance policies and/or exchange traded funds, which are managed by subsidiaries of the Reporting Person, each of which subsidiaries operates under independent management and makes independent voting and investment decisions, (ii) 114,084 Ordinary Shares are held by third-party client accounts managed by a subsidiary of the Reporting Person as portfolio managers, which subsidiary operates under independent management and makes independent investment decisions and has no voting power in the securities held in such client accounts, and (iii) 1,123,014 Ordinary Shares are beneficially held for its own account. Consequently, this Statement shall not be construed as an admission by the Reporting Person that it is the beneficial owner of more than 1,123,014 Ordinary Shares covered by this Statement.
(b)	Percent of class: See Row (11) of the cover page of the Reporting Person above.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: See Row (6) of the cover page of the Reporting Person above and note in Item 4 above.
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: See Row (8) of the cover page of the Reporting Person above and note in Item 4 above.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Harel Insurance Investments & Financial Services Ltd

Signature:	/s/ Alon Kaufman
Name/Title:	Alon Kaufman/Vice President
Date:	10/06/2025

FAQ

What stake in TEVA does Harel Insurance report?

Harel reports beneficial ownership of 58,118,222 ordinary shares, equal to 5.1% of TEVA based on 1,147,150,917 shares outstanding as of June 30, 2025.

Does Harel have sole voting control over these TEVA shares?

No. The filing reports 0 shares with sole voting power and 58,004,138 shares with shared voting power.

How much of the position is held for Harel’s own account versus client accounts?

1,123,014 shares are beneficially held for Harel’s own account; 56,881,124 are held for public client funds and 114,084 are in third-party client accounts.

Is this filing indicating an attempt to influence Teva’s control?

No. The signature includes a certification that the securities were not acquired or held to change or influence control of the issuer.

On what basis was the 5.1% calculated?

The percentage is calculated using 1,147,150,917 ordinary shares outstanding as reported by Teva in its Quarterly Report filed July 30, 2025.